PTC Therapeutics Inc. (PTCT)

36.49
0.21 0.58
NASDAQ : Health Technology
Prev Close 36.28
Open 36.55
Day Low/High 36.24 / 36.81
52 Wk Low/High 27.53 / 48.81
Volume 458.63K
Avg Volume 618.70K
Exchange NASDAQ
Shares Outstanding 61.55M
Market Cap 2.26B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ (ataluren) Slows Disease Progression In Patients With Duchenne Muscular Dystrophy

PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ (ataluren) Slows Disease Progression In Patients With Duchenne Muscular Dystrophy

- Lung function data from the STRIDE Registry show a trend toward delay of decline of pulmonary function compared with those in CINRG Duchenne Natural History1 -

Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented At World Muscle Society Congress

Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented At World Muscle Society Congress

- Risdiplam-treated type 1 babies with SMA continue to achieve major motor milestones-

PTC Therapeutics To Participate At Upcoming Investor Conferences

PTC Therapeutics To Participate At Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J.

PTC Therapeutics Announces Pricing Of Public Offering Of Common Stock

PTC Therapeutics Announces Pricing Of Public Offering Of Common Stock

SOUTH PLAINFIELD, N.J.

PTC Therapeutics Announces Proposed Public Offering Of Common Stock

PTC Therapeutics Announces Proposed Public Offering Of Common Stock

SOUTH PLAINFIELD, N.J.

PTC Therapeutics Celebrates The Fifth Anniversary Of STRIVE Grant Awards By Announcing 2019 Award Winners

PTC Therapeutics Celebrates The Fifth Anniversary Of STRIVE Grant Awards By Announcing 2019 Award Winners

-Global program recognizes excellence and innovation in the Duchenne muscular dystrophy community-

PTC Therapeutics Reports Second Quarter 2019 Financial Results And Provides A Corporate Update

PTC Therapeutics Reports Second Quarter 2019 Financial Results And Provides A Corporate Update

-Translarna™ approved in Brazil & PTC entered first annual contract with Ministry of Health-

PTC Therapeutics Expands Presence In New Jersey By Securing State-of-the-Art Biologics Facility

PTC Therapeutics Expands Presence In New Jersey By Securing State-of-the-Art Biologics Facility

- Facility will support gene therapy production and continued development of pipeline of investigational medicines -

PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement With Odylia Therapeutics

PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement With Odylia Therapeutics

- Collaboration expands PTC's Gene Therapy portfolio to rare ophthalmic diseases -

PTCT August 9th Options Begin Trading

PTCT August 9th Options Begin Trading

Investors in PTC Therapeutics Inc saw new options begin trading today, for the August 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new August 9th contracts and identified one put and one call contract of particular interest.

PTC Therapeutics Receives FDA Approval For The Expansion Of The EMFLAZA® (deflazacort) Labeling To Include Patients 2-5 Years Of Age

PTC Therapeutics Receives FDA Approval For The Expansion Of The EMFLAZA® (deflazacort) Labeling To Include Patients 2-5 Years Of Age

-- Emflaza is the only approved treatment for all patients two and over living with Duchenne muscular dystrophy --

PTC Therapeutics Promotes Emily Hill To Chief Financial Officer

PTC Therapeutics Promotes Emily Hill To Chief Financial Officer

SOUTH PLAINFIELD, N.J.

PTC Therapeutics To Participate At Upcoming Investor Conference

PTC Therapeutics To Participate At Upcoming Investor Conference

SOUTH PLAINFIELD, N.J.

PTC Therapeutics Announces First-Ever Winners Of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders

PTC Therapeutics Announces First-Ever Winners Of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders

- $545,000 awarded to help improve Duchenne muscular dystrophy diagnosis and screening across the globe -

PTC Therapeutics And MRI Interventions Announce Strategic Investment

PTC Therapeutics And MRI Interventions Announce Strategic Investment

- $4 million equity investment to advance delivery device R&D for CNS gene therapy portfolio and other company operations -

PTC Therapeutics To Participate At Upcoming Investor Conferences

PTC Therapeutics To Participate At Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J.

Data From Pivotal FIREFISH And SUNFISH Studies Demonstrate Clinical Benefit Of Risdiplam In Type 1, 2, & 3 Spinal Muscular Atrophy Patients

Data From Pivotal FIREFISH And SUNFISH Studies Demonstrate Clinical Benefit Of Risdiplam In Type 1, 2, & 3 Spinal Muscular Atrophy Patients

Babies with Type 1 SMA from Part 1 of FIREFISH continue to achieve motor milestones including standing

PTC Therapeutics Reports First Quarter 2019 Financial Results And Provides A Corporate Update

PTC Therapeutics Reports First Quarter 2019 Financial Results And Provides A Corporate Update

Translarna™ Approved by Brazilian Health Regulatory Authority (ANVISA)

PTC Therapeutics Breaks Below 200-Day Moving Average - Notable For PTCT

PTC Therapeutics Breaks Below 200-Day Moving Average - Notable For PTCT

In trading on Tuesday, shares of PTC Therapeutics Inc crossed below their 200 day moving average of $37.12, changing hands as low as $37.01 per share. PTC Therapeutics Inc shares are currently trading off about 2.5% on the day.

TheStreet Quant Rating: D (Sell)